Candel Therapeutics said it remains focused on advancing its viral immunotherapy programs and is preparing a planned biologics license application submission by year-end. The update follows newly presented prostate cancer data, signaling continued clinical and regulatory progress. While no financial metrics were disclosed, the milestone supports the company’s development outlook.
Candel Therapeutics said it remains focused on advancing its viral immunotherapy programs and is preparing a planned biologics license application submission by year-end. The update follows newly presented prostate cancer data, signaling continued clinical and regulatory progress. While no financial metrics were disclosed, the milestone supports the company’s development outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
